AZ's Alexion Acquisition Looks Astute Bit Of Business

Offers $39bn For Rare Disease Drug Pioneer

Some analysts are suggesting that AstraZeneca is getting hold of a "scarce and high-quality asset" in Alexion for a very reasonable price and shareholders could demand more than the $175 per share offer on the table.

Sodertalje, Sweden - April 27, 2014: Three purple flags with the logo for Atrazeneca flying in the wind on top of the flagpoles against the blue sky.
aSTRAzENECA FLAGS UP PROMISE OF aLEXION'S RARE DISEASE DRUGS • Source: Archive

It would be the biggest acquisition in the company's history but AstraZeneca PLC’s surprise proposed $39bn takeover of Alexion Pharmaceuticals Inc. looks like a shrewd investment.

Observers of the sector who had been bombarded by COVID-19 vaccines news during the week, including updates on AstraZeneca's own...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.